ReviewDer Pathologe2022
[Grading of tumor regression of gastrointestinal carcinomas after neoadjuvant therapy].
Review in Der Pathologe, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Chemotherapy Response as a Predictor of Survival in Post-neoadjuvant Esophagectomy Specimens.Cureus · 2025Article
- Human patient derived organoids: an emerging precision medicine model for gastrointestinal cancer research.Frontiers in cell and developmental biology · 2024Review
- Prognostic value and clinicopathological correlation of the tumor regression grade in neoadjuvant chemotherapy for gastric adenocarcinoma: a retrospective cohort study.Journal of gastrointestinal oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pre- or perioperative chemo- or radiochemotherapy and subsequent resection is the standard therapy for locally advanced esophageal, gastric, and rectal cancer. A tumor regression grading (TRG; also tumor regression grade) categorizes the extent of the regressive changes after a neoadjuvant treatment. There are several TRG systems for gastrointestinal carcinomas that relate either to the extent of the therapy-induced fibrosis in relation to the residual tumor or the estimated proportion of the residual tumor in the area of the former tumor area. An ideal TRG system shows significant interobserver agreement and offers relevant prognostic information - in most cases a complete or almost complete regression after neoadjuvant therapy is associated with an improved prognosis. In this review, the most commonly used TRG systems for gastrointestinal carcinomas are presented and discussed. In addition, current issues such as the standardization of TRG and the subject of regression in lymph node metastases in the context of a TRG system are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.